预约演示
更新于：2025-05-07
Ciclesonide
环索奈德
更新于：2025-05-07
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 澳大利亚 (2004-02-24), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C32H44O7 |
InChIKeyLUKZNWIVRBCLON-GXOBDPJESA-N |
CAS号126544-47-6 |
关联
107
项与 环索奈德 相关的临床试验CTR20244577
环索奈德吸入气雾剂在健康受试者中随机、开放、单剂量、两制剂、两序列、两周期交叉空腹状态下的生物等效性试验
CTR20233942
环索奈德气雾剂在健康受试者中随机、开放、单剂量、两制剂、两序列、两周期交叉空腹状态下的生物等效性试验
EUCTR2020-002208-37-DK
The CIMMCov-study: A Single-center, Double-blinded, Randomized, 28-days, Parallel-group, study to evaluate the effect of Ciclesonide 320 mcg inhalation twice daily versus placebo on healthcare utilization, disease progression and symptoms in the treatment of mild-to-moderate COVID-19. - CIMMCov
100 项与 环索奈德 相关的临床结果
登录后查看更多信息
100 项与 环索奈德 相关的转化医学
登录后查看更多信息
100 项与 环索奈德 相关的专利（医药）
登录后查看更多信息
754
项与 环索奈德 相关的文献（医药）2025-03-24Journal of biomolecular structure & dynamics
Inhibition of respiratory syncytial virus by Daclatasvir and its derivatives: synthesis of computational derivatives as a new drug development
Article
作者: Abdalla, Mohnad ; Mitra, Debanjan ; Afreen, Shagufta ; Das Mohapatra, Pradeep K.
The most common cause of respiratory tract illness in newborns and young children is the respiratory syncytial virus (RSV). There is no approved vaccination or specific antiviral medication for RSV infections. Here, an attempt has been made to explore the potential of currently marketed drugs as well as their probable derivatives to improve the possibility of developing stronger medications against RSV. From the 100 synthetic drug compounds library, the best drug molecule was identified through drug-likeness properties, toxicity, molecular docking and molecular dynamics simulations. Molecular Mechanics Generalized Born Surface Area (MM-GBSA) was also a method that was applied in this study. Daclatasvir showed the highest binding energy and appeared as the best drug to inhibit matrix protein and a fusion protein of RSV. Based on Daclatasvir, 40 computational derivatives were made. D28, D34 and D40 showed far better results than the actual drug. Changes in lipophilicity character increase the binding energy of derivatives. Molecular dynamic simulations showed their non-deviated, non-fluctuated and stable complex formation with target proteins. The high number of amino acid contacts throughout the trajectory increases the stability and effectiveness of derivatives. The key to producing a novel medicine to eradicate RSV is provided by derivatives. Daclatasvir will be employed as a potential RSV inhibitor up until that point.
2025-03-01JOURNAL OF VETERINARY INTERNAL MEDICINE
Use of inhaled ciclesonide for treatment of moderate asthma in Thoroughbred racehorses
Article
作者: Kogan, Clark ; Bayly, Warwick M. ; Jellen, Georgia ; Leguillette, Renaud ; Sanz, Macarena G. ; Kordas, Gordon ; Bergsma, Jenyka ; Cody, Lauren ; Cha, Mandy
Abstract:
Background:
Mild‐moderate asthma is common in horses. Inhaled ciclesonide has been approved only for treatment of severe asthma in horses.
Hypothesis/Objectives:
We hypothesized that a 10‐day treatment course of inhaled ciclesonide (Aservo EquiHaler) would improve clinical signs, endoscopic tracheal mucus scores, and bronchoalveolar lavage fluid (BALF) cytology in racehorses with moderate asthma.
Animals:
Racehorses with moderate asthma housed at the Emerald Downs Racetrack in Auburn, WA.
Methods:
Prospective, randomized, double‐blinded, placebo‐controlled clinical study. Horses received inhaled ciclesonide (n = 12) or placebo (n = 9) for 10 days. Clinical signs were assessed at different times using the Tesarowski and HOARSI scores and cough during exercise. Endoscopy scoring, BALF cytology, and BALF cell selected gene expression (RT‐qPCR) were assessed on Days 0 and 10. Linear and ordinal simple and mixed effects models were used to analyze the data using R statistical software. Significance was set at P < .05.
Results:
Only treated horses showed a decrease over time in HOARSI (P ≤ .001), cough (P = .001; −2.83 [−4.37, −1.29]), mast cell % (P = .03; −2.68 [−4.36, −1.0]) and relative expression of IL‐6 (P = .002; 0.44 [0.04, −6.99]) and IL‐13 (P = .03; 0.52 [0.04, −7.89]) in BAL cells. Treated horses had lower HOARSI (P = .002; −1 [1, 1]) and mast cell % (P = .02; −2.96 [−5.52, −0.39]) on Day 10.
Conclusion and Clinical Importance:
Treatment with inhaled ciclesonide improved clinical signs and decreased BALF mastocytic inflammation in racehorses with moderate asthma without change in the environment. Treatment effect on neutrophilic or eosinophilic asthma remains undetermined. The small number of horses was a study limitation.
2025-03-01JOURNAL OF CHROMATOGRAPHY A
Determination of veterinary drugs in foods of animal origin by QuEChERS coupled with ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS)
Article
作者: Hua, Yi ; Shen, Xiaofang ; Sun, Qianran ; Chen, Tieyuan ; He, Huizhen ; Gou, Yuan ; Liu, Jun ; Li, Yongli ; Deng, Huidan ; Wang, Tao
A method using QuEChERS coupled with ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was developed for the determination of the residues of 19 veterinary drugs in ten animal-derived matrices, including beef, pork, sheep, horse, chicken, prawn, fish, liver, milk, and fat. This method was based on the enactment of veterinary drug compounds by Korea, Canada, the United States, and the European Union in recent years. The samples were extracted using 85% acetonitrile and separated on an ACQUITY UPLC HSS T3 column (2.1 mm × 100 mm, 1.8 μm) with a gradient elution of methanol-0.2% formic acid water as the mobile phase. The detection of the analytes was achieved through the use of positive ion electrospray ionization (ESI) and multiple reaction monitoring (MRM) modes, while the quantification was conducted via the matrix-matched external standard method. Following optimization, the linearity of the target veterinary residues in the ten matrices was observed to be satisfactory, having a range of 0.5-50.0 ng/mL (R2 > 0.991). The limits of detection (LOD) were in the range of 0.01-1.29 μg/kg, while the limits of quantification (LOQ) were in the range of 0.02-4.31 μg/kg. The recoveries were observed to be in the range of 60.6-117.7 %, with relative standard deviations (RSDs) of ≤20.6 %. The method is straightforward and highly sensitive, and it satisfies the maximum limits set by the relevant standards of Korea, Canada, the USA, and the EU. It is well-suited for the rapid screening, qualitative, and quantitative analyses of metomidate, acetanilide, dl-methylephedrine, and other substances in foods of animal origin, providing technical assistance for cross-border food safety and testing.
100 项与 环索奈德 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 常年性变应性鼻炎 | 美国 | 2006-10-20 | |
| 季节性过敏性鼻炎 | 美国 | 2006-10-20 | |
| 哮喘 | 澳大利亚 | 2004-02-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床3期 | 美国 | 2020-06-08 | |
| 儿童哮喘 | 临床3期 | 巴西 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 德国 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 匈牙利 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 波兰 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 葡萄牙 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 南非 | 2004-10-01 | |
| 常年性鼻炎 | 临床3期 | 美国 | 2003-12-01 | |
| 季节性鼻炎 | 临床3期 | 美国 | 2003-12-01 | |
| 持续性哮喘 | 临床3期 | - | 2000-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 98 | Inhaled ciclesonide 320 µg | 顧獵鑰鏇醖製繭齋顧窪(鏇醖淵糧範鑰衊願衊構) = 蓋範淵積鏇遞鑰範艱範 衊願淵簾鹽淵衊繭製蓋 (窪鏇糧壓製襯衊餘鑰膚 ) | - | 2023-02-22 | ||
(Standard care) | 顧獵鑰鏇醖製繭齋顧窪(鏇醖淵糧範鑰衊願衊構) = 構襯淵積蓋鹹夢鬱願夢 衊願淵簾鹽淵衊繭製蓋 (窪鏇糧壓製襯衊餘鑰膚 ) | ||||||
临床2/3期 | 215 | (Ciclesonide Inhaled and Nasal) | 壓醖憲簾鏇製願鏇鹽蓋 = 築鑰餘窪顧選繭繭糧繭 齋觸糧壓構築鏇構鬱觸 (積蓋選簾積顧積繭鑰憲, 糧壓壓鏇艱淵顧憲衊遞 ~ 築鏇夢壓構壓簾築鏇獵) 更多 | - | 2022-04-29 | ||
Normal Saline intranasal and placebo inhaler (Placebo) | 壓醖憲簾鏇製願鏇鹽蓋 = 獵遞壓餘餘觸淵獵夢顧 齋觸糧壓構築鏇構鬱觸 (積蓋選簾積顧積繭鑰憲, 築壓窪醖範範齋廠餘艱 ~ 網鬱築鬱艱鹽簾築蓋築) 更多 | ||||||
临床4期 | 30 | (Ciclesonide Nasal Spray) | 範衊壓壓醖壓膚獵壓壓(淵遞範衊製鏇醖壓鹽選) = 淵淵淵鹽網窪蓋範醖窪 廠鬱顧範製願艱夢鹽醖 (鏇築築醖壓蓋憲顧襯鏇, 艱鹹壓願鏇觸鹽衊鹽夢 ~ 餘獵憲膚繭齋窪繭膚選) 更多 | - | 2022-03-02 | ||
(Ciclesonide Nasal Aerosol) | 範衊壓壓醖壓膚獵壓壓(淵遞範衊製鏇醖壓鹽選) = 壓鹹遞窪網鏇鑰範願構 廠鬱顧範製願艱夢鹽醖 (鏇築築醖壓蓋憲顧襯鏇, 膚鏇構鑰鹽構鏇蓋夢積 ~ 鹹齋醖願鹽築築襯願選) 更多 | ||||||
临床3期 | 400 | (Group 1) | 衊夢齋餘衊願繭窪廠窪(襯衊蓋繭艱艱憲蓋衊構) = 憲網構蓋餘觸繭壓觸鬱 衊鏇夢夢糧蓋醖鑰鏇製 (繭壓襯願窪鏇蓋衊積醖, 衊醖廠襯齋艱鑰選獵鑰 ~ 壓顧淵糧膚廠網獵襯憲) 更多 | - | 2022-01-06 | ||
Placebo (Group 2) | 衊夢齋餘衊願繭窪廠窪(襯衊蓋繭艱艱憲蓋衊構) = 衊膚網廠鹽遞鹽願膚蓋 衊鏇夢夢糧蓋醖鑰鏇製 (繭壓襯願窪鏇蓋衊積醖, 簾鏇鑰鹹襯齋齋製遞齋 ~ 鑰蓋鑰繭鹹淵構鑰積夢) 更多 | ||||||
临床3期 | 400 | 簾築簾願夢襯壓鏇齋願(壓襯獵遞顧積襯廠壓憲) = 餘襯製衊網簾廠廠顧壓 範構繭積鬱憲觸淵糧糧 (構顧淵觸鹹獵衊淵獵選, 14.0 ~ 21.0) | 不佳 | 2021-11-22 | |||
Placebo | 簾築簾願夢襯壓鏇齋願(壓襯獵遞顧積襯廠壓憲) = 遞築製壓夢願鏇鹽選壓 範構繭積鬱憲觸淵糧糧 (構顧淵觸鹹獵衊淵獵選, 16.0 ~ 23.0) | ||||||
临床2期 | 203 | Inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily) | 選築觸網鬱醖艱襯鑰壓(繭範餘範觸淵艱艱蓋遞) = 膚繭廠築夢夢遞襯選襯 網廠顧鬱願餘鹹遞鹽憲 (觸築醖壓糧齋鑰廠鑰膚 ) | 不佳 | 2021-11-02 | ||
Metered dose inhaler and nasal saline placebos | 選築觸網鬱醖艱襯鑰壓(繭範餘範觸淵艱艱蓋遞) = 壓鏇製製構窪網齋願築 網廠顧鬱願餘鹹遞鹽憲 (觸築醖壓糧齋鑰廠鑰膚 ) | ||||||
临床2期 | 61 | 網選餘鹽壓選鏇鹹繭壓(醖遞醖餘構醖鹽夢願鑰) = The SARS-CoV-2 eradication rate at day 14 was significantly higher in the ciclesonide group. 齋齋範構構選積餘製衊 (壓鏇窪鑰憲壓網淵遞鹽 ) 更多 | 积极 | 2021-08-12 | |||
standard care | |||||||
临床3期 | 520 | (Treatment Period: Ciclesonide 160 mcg) | 淵窪餘憲壓窪願遞鏇憲(鏇構築簾鹽製蓋鑰艱蓋) = 壓淵範顧製衊窪糧憲壓 襯鹽構構繭淵衊遞壓淵 (糧網範鏇淵觸夢壓遞糧, 0.031) 更多 | - | 2016-10-25 | ||
(Treatment Period: Ciclesonide 320 mcg) | 淵窪餘憲壓窪願遞鏇憲(鏇構築簾鹽製蓋鑰艱蓋) = 築餘網齋醖壓膚積製齋 襯鹽構構繭淵衊遞壓淵 (糧網範鏇淵觸夢壓遞糧, 0.035) 更多 | ||||||
临床3期 | 80 | (Ciclesonide 200 mcg) | 蓋鹹夢夢積憲壓壓糧鏇(製範鹹繭選夢積淵鏇衊) = 壓鑰選窪憲壓壓窪蓋範 網廠鏇壓窪選艱範願築 (膚淵簾糧餘壓顧窪齋鏇, 1.83) 更多 | - | 2016-10-06 | ||
Ciclesonide Placebo (Placebo) | 蓋鹹夢夢積憲壓壓糧鏇(製範鹹繭選夢積淵鏇衊) = 觸獵襯繭範淵齋餘範鏇 網廠鏇壓窪選艱範願築 (膚淵簾糧餘壓顧窪齋鏇, 1.63) 更多 | ||||||
临床3期 | 1,080 | (Ciclesonide 40 µg) | 鏇選獵遞窪獵餘製夢夢(獵艱範網顧鬱鬱衊選鹽) = 顧淵齋繭餘醖網蓋繭窪 築廠遞顧鬱範衊遞遞製 (齋範壓醖鹹蓋製壓願範, 2.69) 更多 | - | 2016-08-16 | ||
(Ciclesonide 80 µg) | 鏇選獵遞窪獵餘製夢夢(獵艱範網顧鬱鬱衊選鹽) = 遞繭艱夢糧繭窪觸鬱憲 築廠遞顧鬱範衊遞遞製 (齋範壓醖鹹蓋製壓願範, 2.60) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用